The success of CAR T cell therapies against solid tumors remains limited. Here the authors report the results of a phase 1 trial of PSCA-directed autologous CAR-T cells with pharmacological activation by rimiducid in patients with metastatic pancreatic or prostate cancer.
- Mark N. Stein
- Ecaterina E. Dumbrava
- Carlos R. Becerra